What are the recommended management steps for acute upper gastrointestinal bleeding, including resuscitation, blood transfusion targets, anticoagulant reversal, intravenous proton‑pump inhibitor therapy, endoscopic treatment, and post‑procedure care?

Management of Acute Upper Gastrointestinal Bleeding

For patients with acute upper GI bleeding, initiate immediate resuscitation, transfuse at hemoglobin <7 g/dL (8 g/dL if cardiovascular disease present), perform endoscopy within 24 hours, and use combination endoscopic therapy (epinephrine plus thermal/mechanical modality) for high-risk lesions, followed by high-dose IV PPI therapy (80 mg bolus then 8 mg/hour infusion for 72 hours). 1

Initial Resuscitation and Risk Stratification

Begin with aggressive hemodynamic stabilization using IV fluids for any patient with hemodynamic instability 1. The Glasgow Blatchford Score (GBS) is your primary risk stratification tool—patients with GBS ≤1 can be safely discharged with outpatient endoscopy as they have very low risk of rebleeding or mortality 1, 2. Do not use the AIMS65 score for this purpose, as evidence does not support its use for identifying low-risk patients 1.

Blood Transfusion Strategy

Transfuse red blood cells at hemoglobin threshold of <8 g/L (8 g/dL) in patients without cardiovascular disease 1. For patients with underlying cardiovascular disease, use a higher threshold, though the exact level requires clinical judgment based on evidence of active ischemia 1. This restrictive strategy improves outcomes compared to liberal transfusion.

Pre-Endoscopy Pharmacologic Management

• Administer IV erythromycin (typically 250 mg) before endoscopy to improve gastric visualization 3
• Start PPI therapy pre-endoscopy to potentially downstage lesions and reduce need for intervention, but do not delay endoscopy for this 1
• Do NOT use H2-receptor antagonists, somatostatin, or octreotide for acute ulcer bleeding 1

Anticoagulation Management

Do not delay endoscopy in patients on anticoagulants (warfarin or DOACs)—proceed with endoscopy and hemostatic therapy as needed 1. The risk of delaying diagnosis and treatment outweighs concerns about procedural bleeding risk.

Endoscopic Management

Timing

Perform endoscopy within 24 hours of presentation for all hospitalized patients 1, 2. Urgent endoscopy (<12 hours) does not improve outcomes compared to early endoscopy and is not recommended unless there is ongoing massive bleeding with hemodynamic instability 2.

Endoscopic Therapy Based on Lesion Type

For high-risk stigmata (active spurting/oozing or visible vessel):

• Use combination therapy: epinephrine injection PLUS a second modality (contact thermal therapy, mechanical clips, or sclerosant injection) 1, 2
• Never use epinephrine injection alone—it provides suboptimal efficacy 1
• Acceptable thermal methods include bipolar electrocoagulation, heater probe, or argon plasma coagulation (no single thermal method is superior) 1
• Through-the-scope clips are acceptable but have slightly lower quality evidence than thermal methods 1

For adherent clots: The role of endoscopic therapy is controversial; intensive PPI therapy alone may be sufficient, though endoscopic therapy can be considered 1.

For flat spots or clean-based ulcers: No endoscopic therapy needed 1.

Rescue Therapies

• TC-325 hemostatic powder: Use only as temporizing therapy when conventional methods fail or are unavailable—do NOT use as primary single therapy 1
• Over-the-scope clips (OTSCs): Consider for refractory bleeding after conventional therapy fails 3

Management of Rebleeding

Routine second-look endoscopy is NOT recommended 1. However, if rebleeding occurs, attempt repeat endoscopic therapy first 1. If second endoscopic attempt fails, proceed to transcatheter arterial embolization (TAE) where available, or surgery if TAE unavailable or unsuccessful 1, 2.

Post-Endoscopy Pharmacologic Management

PPI Therapy Protocol

For high-risk lesions treated endoscopically, administer IV PPI as 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours 1, 2. This is a strong recommendation with moderate-quality evidence. Alternative regimens include twice-daily IV or oral PPI, though continuous infusion is preferred 2.

After the initial 72 hours:

• Switch to oral PPI twice daily for 14 days, then once daily thereafter 1
• Continue once-daily PPI long-term based on underlying cause 1

For FIIb lesions (adherent clot) not treated endoscopically, also use high-dose PPI therapy 2.

Hospital Management and Monitoring

• Hospitalize patients with high-risk stigmata for at least 72 hours after endoscopic hemostasis 1
• Low-risk patients can be fed within 24 hours after endoscopy 1
• Obtain surgical consultation for patients in whom endoscopic therapy fails 1

Critical Helicobacter pylori Management

Test all patients with bleeding peptic ulcers for H. pylori and provide eradication therapy if positive, with confirmation of eradication 1. This is essential to prevent recurrent bleeding. If initial testing during acute bleeding is negative, repeat testing as acute-phase testing can yield false negatives 1.

Antiplatelet and Anticoagulation Resumption

• For patients on aspirin for secondary cardiovascular prophylaxis, restart aspirin as soon as cardiovascular risk outweighs bleeding risk, preferably within 3-5 days 1, 2
• Resume anticoagulation within or soon after 7 days once bleeding is controlled, based on thromboembolic risk 2
• Use PPI co-therapy in patients requiring antiplatelet or anticoagulant therapy after ulcer bleeding 1

Common Pitfalls to Avoid

1. Never use epinephrine injection as monotherapy—always combine with thermal or mechanical modality
2. Do not perform routine second-look endoscopy—only repeat if clinical rebleeding occurs
3. Do not delay endoscopy for anticoagulation reversal—proceed with diagnostic and therapeutic endoscopy
4. Do not use liberal transfusion strategies—stick to restrictive thresholds unless active cardiovascular ischemia
5. Do not discharge high-risk patients early—maintain 72-hour observation period after hemostasis
6. Do not forget H. pylori testing and eradication—this prevents recurrence